Quarterly Financial Results for Q2 2026 – Filed July 31, 2026, covering the six-month period ended June 30, 2026, and the three-month quarter ended June 30, 2026, with comparative periods from 2025 Consolidated Financial Statements – Includes unaudited balance sheets as of June 30, 2026 and December 31, 2025; statements of operations for six-month and three-month periods; statements of…

Our analysis rates this filing CAUTIOUS. Organon & Co. faces an ELEVATED concern profile driven by the convergence of three material factors: (1) a major acquisition integration challenge at a critical early execution stage, (2) an extended divestiture process creating operational drag and…

Concern level: HIGH (6.8/10). Key factors: Sun Pharma acquisition (severity 7/10) completed April 26, 2026 introduces material M&A integration risk during early execution phase; complex integration of operations, systems, and personnel required while maintaining existing business performance; Risk trend INCREASING with overall risk score of 6.8/10 indicating deteriorating risk profile; Jada…

Notable risk changes: Sun Pharma acquisition completed April 26, 2026 - major M&A integration risk now active; company must execute complex integration of acquired operations while maintaining existing business performance; Jada business classified as held-for-sale (January 31, 2026) but still operating through H1 2026 - extended timeline creates operational uncertainty and potential for asset impairment if sale…

The model predicts OGN will underperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.